Cepheid (Nasdaq:
CPHD) and
bioMerieux (EPA:
BIM) recently announced their strategic partnership for the development and commercialization of a novel line of sepsis test products on the
GeneXpert platform.
Both companies will jointly develop the products, Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive worldwide basis. The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. Cepheid will continue to complete development, manufacture and market the MRSA products.
Based in Sunnyvale, California, Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets; while bioMerieux is a leading international diagnostics group that specialises in the field of in vitro diagnostics for clinical and industrial applications.
Together, the companies will create the next generation of molecular diagnostics systems.
Find more details from the press release.
.jpg)
Comment Preview